Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Madrigal Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (125)	9/26/2019 11:29:28 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 138

OT: GLMD Aramchol p3/4 trial design similar to MGL-3196, but with FREEDOM to have other (I guess GLP-1 included) anti-diabetic medications at STABLE dose (and no pre-screen weight loss of >5%): Weight loss of more than 5% within 3 months prior to screeningHistory of bariatric surgery within 5 years of liver biopsy or planned surgery for weight reductionTreatment with drugs that may cause NAFLD within 12 months prior to liver biopsyTreatment with some anti-diabetic medications; Unless started prior to biopsy (timeframe depending on drug) and stable clinicaltrials.gov PS: Disclosure (I have LARGE GLMD position, which I may unload at any time..without on-time notice...)